{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:58:19Z","timestamp":1782226699857,"version":"3.54.5"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10555-024-10219-1","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T04:31:35Z","timestamp":1733200295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["CAR T-cell therapy to treat multiple myeloma: current state and future directions"],"prefix":"10.1007","volume":"44","author":[{"given":"Siddhartha Thammineni","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"10219_CR1","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin, Y., Raje, N. S., Berdeja, J. G., et al. (2023). Idecabtagene vicleucel for relapsed and refractory multiple myeloma: Post hoc 18-month follow-up of a phase 1 trial. Nature Medicine, 29, 2286\u20132294.","journal-title":"Nature Medicine"},{"key":"10219_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N., Berdeja, J., Lin, Y., et al. (2019). Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine, 380, 1726\u20131737.","journal-title":"New England Journal of Medicine"},{"key":"10219_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C., Anderson, L. D., Shah, N., et al. (2021). Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384, 705\u2013716.","journal-title":"New England Journal of Medicine"},{"key":"10219_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2020-134322","volume":"136","author":"JG Berdeja","year":"2020","unstructured":"Berdeja, J. G., Raje, N. S., Siegel, D. S., et al. (2020). Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients with relapsed and refractory multiple myeloma: KarMMa subgroup analysis. Blood, 136, 16\u201317.","journal-title":"Blood"},{"key":"10219_CR5","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen, D. K., Sidana, S., Peres, L. C., et al. (2023). Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: Real-world experience from the myeloma CAR T consortium. Journal of Clinical Oncology, 41, 2087\u20132097.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri, C. J., Hildebrandt, M. A. T., Hashmi, H., et al. (2023). Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer Journal, 13, 117.","journal-title":"Blood Cancer Journal"},{"key":"10219_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G., Madduri, D., Usmani, S. Z., et al. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study. Lancet, 398, 314\u2013324.","journal-title":"Lancet"},{"key":"10219_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T., Usmani, S. Z., Berdeja, J. G., et al. (2023). Ciltacabtagene Autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. Journal of Clinical Oncology, 41, 1265\u20131274.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR9","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen, D. K., Patel, K. K., Peres, L. C., et al. (2023). Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM). Journal of Clinical Oncology, 41, 8012\u20138012.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J., Dhakal, B., Yong, K., et al. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. New England Journal of Medicine, 389, 335.","journal-title":"New England Journal of Medicine"},{"key":"10219_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., et al. (2023). Ide-cel or standard regimens in relapsed and refractory multiple myeloma. New England Journal of Medicine, 388, 1002\u20131014.","journal-title":"New England Journal of Medicine"},{"key":"10219_CR12","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K., Rajkumar, V., Kyle, R. A., et al. (2017). Multiple myeloma. Nature Reviews Disease Primers, 3, 17046.","journal-title":"Nature Reviews Disease Primers"},{"key":"10219_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S., Paiva, B., Anderson, K. C., et al. (2016). International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology, 17, e328\u2013e346.","journal-title":"The Lancet Oncology"},{"key":"10219_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar, S. V., & Kumar, S. (2016). Multiple myeloma: Diagnosis and treatment. Mayo Clinic Proceedings, 91, 101\u2013119.","journal-title":"Mayo Clinic Proceedings"},{"key":"10219_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos, E., Mikhael, J., Hajek, R., et al. (2021). Management of patients with multiple myeloma beyond the clinical-trial setting: Understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 11, 40.","journal-title":"Blood Cancer Journal"},{"key":"10219_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A., & June, C. H. (2017). The principles of engineering immune cells to treat cancer. Cell, 168, 724\u2013740.","journal-title":"Cell"},{"key":"10219_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 17, 147\u2013167.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10219_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., RiviSre, I., & Riddell, S. (2017). Therapeutic T cell engineering. Nature, 545, 423\u2013431.","journal-title":"Nature"},{"key":"10219_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava, S., & Riddell, S. R. (2015). Engineering CAR-T cells: Design concepts. Trends in Immunology, 36, 494\u2013502.","journal-title":"Trends in Immunology"},{"key":"10219_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11, 69.","journal-title":"Blood Cancer Journal"},{"key":"10219_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A., Shi, V., Maric, I., et al. (2016). T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood, 128, 1688\u20131700.","journal-title":"Blood"},{"key":"10219_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","volume":"14","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., et al. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: A narrative review. Blood Cancer Journal, 14, 24.","journal-title":"Blood Cancer Journal"},{"key":"10219_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L., & Kochenderfer, J. N. (2021). CAR T cell therapies for patients with multiple myeloma. Nature Reviews. Clinical Oncology, 18, 71\u201384.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10219_CR24","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., et al. (2013). B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research, 19, 2048\u20132060.","journal-title":"Clinical Cancer Research"},{"key":"10219_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J., Darce, J. R., Arendt, B. K., et al. (2004). Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood, 103, 689\u2013694.","journal-title":"Blood"},{"key":"10219_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O'Connor","year":"2004","unstructured":"O\u2019Connor, B. P., Raman, V. S., Erickson, L. D., et al. (2004). BCMA is essential for the survival of long-lived bone marrow plasma cells. Journal of Experimental Medicine, 199, 91\u201398.","journal-title":"Journal of Experimental Medicine"},{"key":"10219_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ymthe.2023.12.018","volume":"32","author":"L Mikkilineni","year":"2024","unstructured":"Mikkilineni, L., Natrakul, D. A., Lam, N., et al. (2024). Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. Molecular Therapy, 32, 503\u2013526.","journal-title":"Molecular Therapy"},{"key":"10219_CR28","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N., Maric, I., Hartman, S. D., et al. (2018). T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. Journal of Clinical Oncology, 36, 2267\u20132280.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR29","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith, E. L., Harrington, K., Staehr, M., et al. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine, 11, eaau7746.","journal-title":"Science Translational Medicine"},{"key":"10219_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2023-181857","volume":"142","author":"S Bal","year":"2023","unstructured":"Bal, S., Htut, M., Nadeem, O., et al. (2023). BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): Updated results from a phase 1 study. Blood, 142, 219.","journal-title":"Blood"},{"key":"10219_CR31","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A., Minnema, M. C., Berdeja, J. G., et al. (2022). Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. New England Journal of Medicine, 387, 2232\u20132244.","journal-title":"New England Journal of Medicine"},{"key":"10219_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S., Devlin, S. M., Landa, J., et al. (2022). GPRC5D-targeted CAR T cells for myeloma. New England Journal of Medicine, 387, 1196\u20131206.","journal-title":"New England Journal of Medicine"},{"key":"10219_CR33","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith, E. L., Harrington, K., Staehr, M., et al. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine, 11, eaau7746.","journal-title":"Science Translational Medicine"},{"key":"10219_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li, J., Stagg, N. J., Johnston, J., et al. (2017). Membrane-proximal epitope facilitates efficient T cell synapse formation by Anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell, 31, 383\u2013395.","journal-title":"Cancer Cell"},{"key":"10219_CR35","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","volume":"29","author":"C Amatya","year":"2021","unstructured":"Amatya, C., Pegues, M. A., Lam, N., et al. (2021). Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7. Molecular Therapy, 29, 702\u2013717.","journal-title":"Molecular Therapy"},{"key":"10219_CR36","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","volume":"130","author":"T Gogishvili","year":"2017","unstructured":"Gogishvili, T., Danhof, S., Prommersberger, S., et al. (2017). SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. Blood, 130, 2838\u20132847.","journal-title":"Blood"},{"key":"10219_CR37","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1158\/1078-0432.CCR-16-1421","volume":"23","author":"QJ Wang","year":"2017","unstructured":"Wang, Q. J., Yu, Z., Hanada, K.-I., et al. (2017). Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers. Clinical cancer research\u202f: An official journal of the American Association for Cancer Research, 23, 2267\u20132276.","journal-title":"Clinical cancer research : An official journal of the American Association for Cancer Research"},{"key":"10219_CR38","doi-asserted-by":"publisher","first-page":"7891","DOI":"10.3390\/curroncol30090573","volume":"30","author":"E Chu","year":"2023","unstructured":"Chu, E., Wu, J., Kang, S. S., et al. (2023). SLAMF7 as a promising immunotherapeutic target in multiple myeloma treatments. Current Oncology, 30, 7891\u20137903.","journal-title":"Current Oncology"},{"key":"10219_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2023-182578","volume":"142","author":"C Kasap","year":"2023","unstructured":"Kasap, C., Izgutdina, A., Patino Escobar, B., et al. (2023). Discovery and development of CD70 as a cellular therapy target in high risk multiple myeloma. Blood, 142, 465.","journal-title":"Blood"},{"key":"10219_CR40","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M., & Kochenderfer, J. N. (2023). Long-term outcomes following CAR T cell therapy: What we know so far. Nature Reviews Clinical Oncology, 20, 359\u2013371.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10219_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman, K. M., Garrett, T. E., Evans, J. W., et al. (2018). Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Human Gene Therapy, 29, 585\u2013601.","journal-title":"Human Gene Therapy"},{"key":"10219_CR42","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2019.09.267","volume":"19","author":"X Fan","year":"2019","unstructured":"Fan, X., Zhuang, Q., Yang, L., et al. (2019). Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed\/refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 19, e160.","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"key":"10219_CR43","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","volume":"24","author":"BK Jin","year":"2023","unstructured":"Jin, B. K., Odongo, S., Radwanska, M., et al. (2023). Nanobodies: A review of generation, diagnostics and therapeutics. International Journal of Molecular Sciences, 24, 5994.","journal-title":"International Journal of Molecular Sciences"},{"key":"10219_CR44","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O., Aleman, A., Upadhyaya, B., et al. (2021). Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 27, 2099\u20132103.","journal-title":"Nature Medicine"},{"key":"10219_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen, A. D., Parekh, S., Santomasso, B. D., et al. (2022). Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 12, 32.","journal-title":"Blood Cancer Journal"},{"key":"10219_CR46","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin, Y., Martin, T. G., Usmani, S. Z., et al. (2023). CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. Journal of Clinical Oncology, 41, 8009\u20138009.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","volume":"39","author":"T Martin","year":"2023","unstructured":"Martin, T., Usmani, S. Z., Schecter, J. M., et al. (2023). Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Current Medical Research and Opinion, 39, 81\u201389.","journal-title":"Current Medical Research and Opinion"},{"key":"10219_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen, A. D., Mateos, M.-V., Cohen, Y. C., et al. (2023). Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood, 141, 219\u2013230.","journal-title":"Blood"},{"key":"10219_CR49","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","volume":"21","author":"JM Buonato","year":"2022","unstructured":"Buonato, J. M., Edwards, J. P., Zaritskaya, L., et al. (2022). Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain. Molecular Cancer Therapeutics, 21, 1171\u20131183.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10219_CR50","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault, M. J., Bishop, M. R., Rosenblatt, J., et al. (2023). Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Advances, 7, 768\u2013777.","journal-title":"Blood Advances"},{"key":"10219_CR51","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood-2023-189761","volume":"142","author":"MJ Frigault","year":"2023","unstructured":"Frigault, M. J., Rosenblatt, J., Dhakal, B., et al. (2023). Phase 1 study of CART-Ddbcma for the treatment of patients with relapsed and\/or refractory multiple myeloma: Results from at least 1-year follow-up in all patients. Blood, 142, 1023\u20131023.","journal-title":"Blood"},{"key":"10219_CR52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41417-023-00712-0","volume":"31","author":"Q Wang","year":"2024","unstructured":"Wang, Q., Wei, R., Guo, S., et al. (2024). An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously. Cancer Gene Therapy, 31, 420\u2013426.","journal-title":"Cancer Gene Therapy"},{"key":"10219_CR53","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1182\/blood-2019-128468","volume":"134","author":"C Li","year":"2019","unstructured":"Li, C., Wang, J., Wang, D., et al. (2019). Efficacy and safety of fully human Bcma targeting CAR T cell therapy in relapsed\/refractory multiple myeloma. Blood, 134, 929\u2013929.","journal-title":"Blood"},{"key":"10219_CR54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam, N., Trinklein, N. D., Buelow, B., et al. (2020). Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nature Communications, 11, 283.","journal-title":"Nature Communications"},{"key":"10219_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"W-H Zhao","year":"2018","unstructured":"Zhao, W.-H., Liu, J., Wang, B.-Y., et al. (2018). A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. Journal of Hematology & Oncology, 11, 141.","journal-title":"Journal of Hematology & Oncology"},{"key":"10219_CR56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell, K. M., & Kochenderfer, J. N. (2021). A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nature Reviews Clinical Oncology, 18, 715\u2013727.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10219_CR57","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/j.iotech.2023.100375","volume":"18","author":"H Balke-Want","year":"2023","unstructured":"Balke-Want, H., Keerthi, V., Cadinanos-Garai, A., et al. (2023). Non-viral chimeric antigen receptor (CAR) T cells going viral. Immuno-Oncology and Technology, 18, 100375.","journal-title":"Immuno-Oncology and Technology"},{"key":"10219_CR58","doi-asserted-by":"publisher","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","volume":"13","author":"N Watanabe","year":"2022","unstructured":"Watanabe, N., Mo, F., & McKenna, M. K. (2022). Impact of manufacturing procedures on CAR T cell functionality. Frontiers in Immunology, 13, 876339.","journal-title":"Frontiers in Immunology"},{"key":"10219_CR59","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer, J. N., Somerville, R. P. T., Lu, T., et al. (2017). Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. Journal of Clinical Oncology, 35, 1803\u20131813.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno, J. N., & Kochenderfer, J. N. (2019). Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Reviews, 34, 45\u201355.","journal-title":"Blood Reviews"},{"key":"10219_CR61","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines, M. R., Knight, T. E., McNerney, K. O., et al. (2023). Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplantation and Cellular Therapy, 29, 438.e1-438.e16.","journal-title":"Transplantation and Cellular Therapy"},{"key":"10219_CR62","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W., Santomasso, B. D., Locke, F. L., et al. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25, 625\u2013638.","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10219_CR63","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","volume":"130","author":"L Mikkilineni","year":"2017","unstructured":"Mikkilineni, L., & Kochenderfer, J. N. (2017). Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood, 130, 2594\u20132602.","journal-title":"Blood"},{"key":"10219_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S., Tummala, S., Kebriaei, P., et al. (2018). Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nature Reviews Clinical Oncology, 15, 47\u201362.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10219_CR65","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.hoc.2023.05.010","volume":"37","author":"R Epperly","year":"2023","unstructured":"Epperly, R., Giordani, V. M., Mikkilineni, L., et al. (2023). Early and late toxicities of chimeric antigen receptor T-cells. Hematology\/Oncology Clinics of North America, 37, 1169.","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10219_CR66","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust, J., Ponce, R., Liles, W. C., et al. (2020). Cytokines in CAR T cell\u2013associated neurotoxicity. Frontiers in Immunology, 11, 577027.","journal-title":"Frontiers in Immunology"},{"key":"10219_CR67","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau, N., Liang, E. C., Wu, Q. V., et al. (2023). Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplantation and cellular therapy, 29, 430\u2013437.","journal-title":"Transplantation and cellular therapy"},{"key":"10219_CR68","first-page":"406","volume":"29","author":"NV Frey","year":"2023","unstructured":"Frey, N. V. (2023). Thinking clearly with anakinra. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 29, 406\u2013407.","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"key":"10219_CR69","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park, J. H., Nath, K., Devlin, S. M., et al. (2023). CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results. Nature Medicine, 29, 1710\u20131717.","journal-title":"Nature Medicine"},{"key":"10219_CR70","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood.2023021860","volume":"142","author":"J Gust","year":"2023","unstructured":"Gust, J. (2023). BCMA-CAR T-cell treatment\u2013associated parkinsonism. Blood, 142, 1181\u20131183.","journal-title":"Blood"},{"key":"10219_CR71","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia, P., Miller, K. C., Yee, A. J., et al. (2023). Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood, 142, 1243\u20131248.","journal-title":"Blood"},{"key":"10219_CR72","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham, C. E., Lee, W.-H., Wiggin, H. R., et al. (2023). Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity. Blood, 142, 1248\u20131252.","journal-title":"Blood"},{"key":"10219_CR73","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1080\/10428194.2022.2056172","volume":"63","author":"JN Brudno","year":"2022","unstructured":"Brudno, J. N., Natrakul, D., Lam, N., et al. (2022). Acute and delayed cytopenias following CAR T-cell therapy: An investigation of risk factors and mechanisms. Leukemia & Lymphoma, 63, 1849\u20131860.","journal-title":"Leukemia & Lymphoma"},{"key":"10219_CR74","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain, T., Olson, T. S., & Locke, F. L. (2023). How I treat cytopenias after CAR T-cell therapy. Blood, 141, 2460\u20132469.","journal-title":"Blood"},{"key":"10219_CR75","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/cancers14061501","volume":"14","author":"N Sharma","year":"2022","unstructured":"Sharma, N., Reagan, P. M., & Liesveld, J. L. (2022). Cytopenia after CAR-T cell therapy\u2014A brief review of a complex problem. Cancers, 14, 1501.","journal-title":"Cancers"},{"key":"10219_CR76","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1182\/blood-2022-165600","volume":"140","author":"MP Hamilton","year":"2022","unstructured":"Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., et al. (2022). Higher rates of severe infection and persistent cytopenias in long-term CAR19 responders than after autologous HCT: A single institution study of 139 subjects. Blood, 140, 7545\u20137547.","journal-title":"Blood"},{"key":"10219_CR77","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","volume":"5","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L., Yates, B., Steinberg, S. M., et al. (2021). Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. Blood Advances, 5, 5312\u20135322.","journal-title":"Blood Advances"},{"key":"10219_CR78","doi-asserted-by":"publisher","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","volume":"28","author":"E M\u00e1rquez-Algaba","year":"2022","unstructured":"M\u00e1rquez-Algaba, E., Iacoboni, G., Pernas, B., et al. (2022). Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 28, 851.e1-851.e8.","journal-title":"Transplantation and Cellular Therapy"},{"key":"10219_CR79","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","volume":"10","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn, K., Palomba, M. L., Pennisi, M., et al. (2020). Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 10, 79.","journal-title":"Blood Cancer Journal"},{"key":"10219_CR80","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"ML Jennifer","year":"2020","unstructured":"Jennifer, M. L., Elisa, Z., Christina, A. B., et al. (2020). Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica, 106, 978\u2013986.","journal-title":"Haematologica"},{"key":"10219_CR81","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/14787210.2022.2128762","volume":"20","author":"G Telli Dizman","year":"2022","unstructured":"Telli Dizman, G., Aguado, J. M., & Fernandez-Ruiz, M. (2022). Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: Systematic review and meta-analysis. Expert Review of Anti-Infective Therapy, 20, 1455\u20131476.","journal-title":"Expert Review of Anti-Infective Therapy"},{"key":"10219_CR82","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/curroncol29020044","volume":"29","author":"C Zu","year":"2022","unstructured":"Zu, C., Xu, Y., Wang, Y., et al. (2022). Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed\/refractory multiple myeloma. Current Oncology, 29, 490\u2013496.","journal-title":"Current Oncology"},{"key":"10219_CR83","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2022.281719","volume":"108","author":"G Chen","year":"2023","unstructured":"Chen, G., Herr, M., Nowak, J., et al. (2023). Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica, 108, 615\u2013620.","journal-title":"Haematologica"},{"key":"10219_CR84","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1002\/jmv.27257","volume":"93","author":"E Cousin","year":"2021","unstructured":"Cousin, E., Belicard, F., Michel, L., et al. (2021). Severe cytomegalovirus disease with encephalitis after CAR-T cell therapy: A rare but potentially fatal complication. Journal of Medical Virology, 93, 6398\u20136403.","journal-title":"Journal of Medical Virology"},{"key":"10219_CR85","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.1182\/blood-2022-167908","volume":"140","author":"F Khawaja","year":"2022","unstructured":"Khawaja, F., Prakash, R., Sassine, J., et al. (2022). Cytomegalovirus (CMV) reactivation within in the first year after chimeric antigen receptor (CAR) T cell therapy: Experience from the first two years at a major cancer center. Blood, 140, 7533\u20137535.","journal-title":"Blood"},{"key":"10219_CR86","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijid.2021.09.061","volume":"112","author":"G Handley","year":"2021","unstructured":"Handley, G., Khawaja, F., Kondapi, D. S., et al. (2021). Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy. International Journal of Infectious Diseases, 112, 327\u2013329.","journal-title":"International Journal of Infectious Diseases"},{"key":"10219_CR87","doi-asserted-by":"publisher","unstructured":"Rebechi, M. T., Bork, J. T., & Riedel, D. J. (2021). HHV-6 encephalitis after chimeric antigen receptor T-cell therapy (CAR-T): 2 case reports and a brief review of the literature. Open Forum Infectious Diseases, 8(11), ofab470. https:\/\/doi.org\/10.1093\/ofid\/ofab470","DOI":"10.1093\/ofid\/ofab470"},{"key":"10219_CR88","doi-asserted-by":"publisher","first-page":"304 e1","DOI":"10.1016\/j.jtct.2022.03.005","volume":"28","author":"S Josyula","year":"2022","unstructured":"Josyula, S., Pont, M. J., Dasgupta, S., et al. (2022). Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma. Transplantation and Cellular Therapy, 28, 304 e1-304 e9.","journal-title":"Transplantation and Cellular Therapy"},{"key":"10219_CR89","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J., Nguyen, T., Rahman, M., et al. (2023). CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood, 142, 6939\u20136939.","journal-title":"Blood"},{"key":"10219_CR90","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G., Fraietta, J. A., Gerson, J. N., et al. (2024). T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nature Medicine, 30, 984\u2013989.","journal-title":"Nature Medicine"},{"key":"10219_CR91","doi-asserted-by":"publisher","first-page":"8025","DOI":"10.1200\/JCO.2023.41.16_suppl.8025","volume":"41","author":"C Li","year":"2023","unstructured":"Li, C., Wang, D., Song, Y., et al. (2023). CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: Updated results of phase 1b\/2 study (FUMANBA-1). Journal of Clinical Oncology, 41, 8025\u20138025.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR92","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.1182\/blood-2022-166465","volume":"140","author":"C Li","year":"2022","unstructured":"Li, C., Wang, D., Fang, B., et al. (2022). Updated results of fumanba-1: A phase 1b\/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and\/or refractory multiple myeloma. Blood, 140, 7435\u20137436.","journal-title":"Blood"},{"key":"10219_CR93","doi-asserted-by":"publisher","first-page":"7433","DOI":"10.1182\/blood-2022-159156","volume":"140","author":"L Mikkilineni","year":"2022","unstructured":"Mikkilineni, L., Manasanch, E. E., Natrakul, D., et al. (2022). T cells expressing a fully-human anti-BCMA chimeric antigen receptor with a heavy-chain-only antigen-recognition domain exhibit rapid and durable activity against multiple myeloma. Blood, 140, 7433\u20137434.","journal-title":"Blood"},{"key":"10219_CR94","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/blood-2022-160038","volume":"140","author":"LJ Costa","year":"2022","unstructured":"Costa, L. J., Kumar, S. K., Atrash, S., et al. (2022). Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). Blood, 140, 1360\u20131362.","journal-title":"Blood"},{"key":"10219_CR95","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S., Matous, J. V., Chhabra, S., et al. (2023). Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results. Nature Medicine, 29, 422\u2013429.","journal-title":"Nature Medicine"},{"key":"10219_CR96","doi-asserted-by":"publisher","first-page":"e9863287","DOI":"10.1097\/01.HS9.0000967684.98632.87","volume":"7","author":"S Bal","year":"2023","unstructured":"Bal, S., Berdeja, J., Htut, M., et al. (2023). S193: BMS-986393 (CC-95266), A G protein\u2013coupled receptor class C group 5 member D (GPRC5D)\u2013Targeted CAR T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): Results from a Phase 1 study. Hemasphere, 7, e9863287.","journal-title":"Hemasphere"},{"key":"10219_CR97","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M., et al. (2017). T memory stem cells in health and disease. Nature Medicine, 23, 18\u201327.","journal-title":"Nature Medicine"},{"key":"10219_CR98","doi-asserted-by":"publisher","first-page":"8941260","DOI":"10.1155\/2016\/8941260","volume":"2016","author":"J Reiser","year":"2016","unstructured":"Reiser, J., & Banerjee, A. (2016). Effector, memory, and dysfunctional CD8(+) T Cell fates in the antitumor immune response. Journal of Immunology Research, 2016, 8941260.","journal-title":"Journal of Immunology Research"},{"key":"10219_CR99","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1182\/blood-2002-11-3577","volume":"101","author":"J Geginat","year":"2003","unstructured":"Geginat, J., Lanzavecchia, A., & Sallusto, F. (2003). Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood, 101, 4260\u20134266.","journal-title":"Blood"},{"key":"10219_CR100","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/JLB.5MR0520-466R","volume":"108","author":"KM Quinn","year":"2020","unstructured":"Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., et al. (2020). Impact of age-, cancer-, and treatment-driven inflammation on T cell function and immunotherapy. Journal of Leukocyte Biology, 108, 953\u2013965.","journal-title":"Journal of Leukocyte Biology"},{"key":"10219_CR101","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry, E. J., Ha, S. J., Kaech, S. M., et al. (2007). Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity, 27, 670\u2013684.","journal-title":"Immunity"},{"key":"10219_CR102","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall, A. L., Dancy, E. K., Cohen, A. D., et al. (2019). T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances, 3, 2812\u20132815.","journal-title":"Blood Advances"},{"key":"10219_CR103","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s43018-023-00567-2","volume":"4","author":"ME Kohler","year":"2023","unstructured":"Kohler, M. E., & Fry, T. J. (2023). CD4+ CAR T cells \u2014 More than helpers. Nature Cancer, 4, 928\u2013929.","journal-title":"Nature Cancer"},{"key":"10219_CR104","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., et al. (2019). B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation, 129, 2210\u20132221.","journal-title":"The Journal of Clinical Investigation"},{"key":"10219_CR105","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S., Matous, J. V., Chhabra, S., et al. (2023). Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results. Nature medicine, 29, 422\u2013429.","journal-title":"Nature medicine"},{"key":"10219_CR106","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu, J., Chen, L. J., Yang, S. S., et al. (2019). Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A, 116, 9543\u20139551.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10219_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876339","volume":"13","author":"N Watanabe","year":"2022","unstructured":"Watanabe, N., Mo, F., & McKenna, M. K. (2022). Impact of manufacturing procedures on CAR T cell functionality. Frontiers in Immunology, 13, 876339.","journal-title":"Frontiers in Immunology"},{"key":"10219_CR108","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","volume":"40","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim, M., Melief, J., Pico de Coa\u00f1a, Y., et al. (2021). Counteracting CAR T cell dysfunction. Oncogene, 40, 421\u2013435.","journal-title":"Oncogene"},{"key":"10219_CR109","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-140410","volume":"136","author":"M Alsina","year":"2020","unstructured":"Alsina, M., Shah, N., Raje, N. S., et al. (2020). Updated results from the phase I CRB-402 study of Anti-Bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: Correlation of expansion and duration of response with T cell phenotypes. Blood, 136, 25\u201326.","journal-title":"Blood"},{"key":"10219_CR110","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/blood-2021-146518","volume":"138","author":"NS Raje","year":"2021","unstructured":"Raje, N. S., Shah, N., Jagannath, S., et al. (2021). Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma. Blood, 138, 548\u2013548.","journal-title":"Blood"},{"key":"10219_CR111","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-142426","volume":"136","author":"OC Finney","year":"2020","unstructured":"Finney, O. C., Yeri, A., Mao, P., et al. (2020). Molecular and phenotypic profiling of drug product and post-infusion samples from CRB-402, an ongoing: Phase I clinical study of bb21217 a BCMA-directed CAR T cell therapy. Blood, 136, 3\u20134.","journal-title":"Blood"},{"key":"10219_CR112","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2020.266841","volume":"108","author":"X Zhou","year":"2023","unstructured":"Zhou, X., Rasche, L., Kort\u00fcm, K. M., et al. (2023). BCMA loss in the epoch of novel immunotherapy for multiple myeloma: From biology to clinical practice. Haematologica, 108, 958\u2013968.","journal-title":"Haematologica"},{"key":"10219_CR113","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1182\/bloodadvances.2019000466","volume":"3","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D., Garfall, A. L., Dogan, A., et al. (2019). Serial treatment of relapsed\/refractory multiple myeloma with different BCMA-targeting therapies. Blood Advances, 3, 2487\u20132490.","journal-title":"Blood Advances"},{"key":"10219_CR114","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00109-009-0531-7","volume":"87","author":"SK Brennan","year":"2009","unstructured":"Brennan, S. K., & Matsui, W. (2009). Cancer stem cells: Controversies in multiple myeloma. Journal of Molecular Medicine, 87, 1079.","journal-title":"Journal of Molecular Medicine"},{"key":"10219_CR115","first-page":"121","volume-title":"Oncogenomics","author":"F Dammacco","year":"2019","unstructured":"Dammacco, F., Leone, P., Silvestris, F., et al. (2019). Chapter 9 - Cancer stem cells in multiple myeloma and the development of novel therapeutic strategies. In F. Dammacco & F. Silvestris (Eds.), Oncogenomics (pp. 121\u2013137). Academic Press."},{"key":"10219_CR116","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/bjh.12563","volume":"163","author":"R Hajek","year":"2013","unstructured":"Hajek, R., Okubote, S. A., & Svachova, H. (2013). Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. British Journal of Haematology, 163, 551\u2013564.","journal-title":"British Journal of Haematology"},{"key":"10219_CR117","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","volume":"373","author":"L Garfall Alfred","year":"2015","unstructured":"Garfall Alfred, L., Maus Marcela, V., Hwang, W.-T., et al. (2015). Chimeric antigen receptor T cells against CD19 for multiple myeloma. New England Journal of Medicine, 373, 1040\u20131047.","journal-title":"New England Journal of Medicine"},{"key":"10219_CR118","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino, L., Di Blasi, R., Kanoun, S., et al. (2020). Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Advances, 4, 5607\u20135615.","journal-title":"Blood Advances"},{"key":"10219_CR119","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil, L. J., Jain, M. D., Feng, L., et al. (2020). Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium. Journal of Clinical Oncology, 38, 3119\u20133128.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR120","doi-asserted-by":"publisher","first-page":"10402","DOI":"10.1182\/blood-2022-167804","volume":"140","author":"R Villanueva","year":"2022","unstructured":"Villanueva, R., Hansen, D. K., Tonseth, R. P., et al. (2022). High metabolic tumor volume is associated with higher toxicity and decreased efficacy of BCMA CAR-T cell therapy in multiple myeloma. Blood, 140, 10402\u201310404.","journal-title":"Blood"},{"key":"10219_CR121","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/blood-2023-190019","volume":"142","author":"CTR Vegivinti","year":"2023","unstructured":"Vegivinti, C. T. R., Lawrence Alexander Santhi, J., Liu, L., et al. (2023). Efficacy of bispecific antibodies vs CAR-T in the treatment of extramedullary disease and high-risk cytogenetics in relapsed multiple myeloma: A systematic review and meta-analysis. Blood, 142, 1994.","journal-title":"Blood"},{"key":"10219_CR122","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3390\/cancers13092018","volume":"13","author":"FM Uckun","year":"2021","unstructured":"Uckun, F. M. (2021). Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers (Basel), 13, 2018.","journal-title":"Cancers (Basel)"},{"key":"10219_CR123","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V., Barber-Rotenberg, J. S., Jung, I. Y., et al. (2022). PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial. Nature Medicine, 28, 724\u2013734.","journal-title":"Nature Medicine"},{"key":"10219_CR124","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M., Kopecky, C., Hombach, A. A., et al. (2011). IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Research, 71, 5697\u20135706.","journal-title":"Cancer Research"},{"key":"10219_CR125","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar, R., Rivas, C., Huynh, M., et al. (2019). NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunology Research, 7, 363\u2013375.","journal-title":"Cancer Immunology Research"},{"key":"10219_CR126","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner, R. M., Sakemura, R., Cox, M. J., et al. (2019). GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, 133, 697\u2013709.","journal-title":"Blood"},{"key":"10219_CR127","doi-asserted-by":"publisher","unstructured":"Hashmi, H., Hansen, D. K., Peres, L. C., Puglianini, O. C., Freeman, C., De Avila, G., ... & Alsina, M. (2024). Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica, 109(5), 1514\u20131524. https:\/\/doi.org\/10.3324\/haematol.2023.283888","DOI":"10.3324\/haematol.2023.283888"},{"issue":"11","key":"10219_CR128","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen, D. K., Sidana, S., Peres, L. C., et al. (2023). Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: Real-world experience from the myeloma CAR T consortium. Journal of Clinical Oncology, 41(11), 2087\u20132097.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR129","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3324\/haematol.2022.282510","volume":"108","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann, N., Ayuk, F. A., Klyuchnikov, E., et al. (2023). Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: A meta-analysis of 723 patients. Haematologica, 108, 2799\u20132802.","journal-title":"Haematologica"},{"key":"10219_CR130","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann, N., Dima, D., Merz, M., et al. (2024). Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. Journal of Clinical Oncology, 42, 1665.","journal-title":"Journal of Clinical Oncology"},{"key":"10219_CR131","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","volume":"4","author":"B Paiva","year":"2023","unstructured":"Paiva, B., Manrique, I., Rytlewski, J., et al. (2023). Time-dependent prognostic value of serological and measurable residual disease assessments after Idecabtagene Vicleucel. Blood Cancer Discov, 4, 365\u2013373.","journal-title":"Blood Cancer Discov"},{"key":"10219_CR132","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/01.HS9.0000846712.74284.0f","volume":"6","author":"Y Lin","year":"2022","unstructured":"Lin, Y., Martin, T., Berdeja, J. G., et al. (2022). P961: Ciltacabtagene Autoleucel, A BCMA-Directed CAR-T cell therapy, in patients with relapsed\/refractory multiple myeloma: 2-year post lpi results from the phase 1B\/2 cartitude-1 study. HemaSphere, 6, 851\u2013852.","journal-title":"HemaSphere"},{"key":"10219_CR133","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood-2022-160370","volume":"140","author":"H Hosoya","year":"2022","unstructured":"Hosoya, H., Carleton, M., Tanaka, K. L., et al. (2022). Disease characterization and response prediction in myeloma patients undergoing conventional and cellular therapies from circulating tumor DNA. Blood, 140, 1546\u20131548.","journal-title":"Blood"},{"key":"10219_CR134","doi-asserted-by":"publisher","first-page":"15086","DOI":"10.1038\/ncomms15086","volume":"8","author":"O Kis","year":"2017","unstructured":"Kis, O., Kaedbey, R., Chow, S., et al. (2017). Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nature Communications, 8, 15086.","journal-title":"Nature Communications"},{"key":"10219_CR135","doi-asserted-by":"publisher","first-page":"786451","DOI":"10.3389\/fonc.2022.786451","volume":"12","author":"B Dhakal","year":"2022","unstructured":"Dhakal, B., Sharma, S., Balcioglu, M., et al. (2022). Assessment of molecular residual disease using circulating tumor DNA to identify multiple myeloma patients at high risk of relapse. Frontiers in Oncology, 12, 786451.","journal-title":"Frontiers in Oncology"},{"key":"10219_CR136","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1038\/bcj.2017.90","volume":"7","author":"T Jelinek","year":"2017","unstructured":"Jelinek, T., Bezdekova, R., Zatopkova, M., et al. (2017). Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal, 7, e617.","journal-title":"Blood Cancer Journal"},{"key":"10219_CR137","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","volume":"67","author":"P Langerhorst","year":"2021","unstructured":"Langerhorst, P., Noori, S., Zajec, M., et al. (2021). Multiple myeloma minimal residual disease detection: Targeted mass spectrometry in blood vs next-generation sequencing in bone marrow. Clinical Chemistry, 67, 1689\u20131698.","journal-title":"Clinical Chemistry"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10219-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10219-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10219-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T03:26:51Z","timestamp":1743478011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10219-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10219"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10219-1","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"14"}}